Presentations

16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009

Posters

  1. Interruption of Antiretroviral Therapy and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in SMART Viral Hepatitis Coinfected Participants and Matched Controls. L Peters, J Neuhaus, A Mocroft, V Soriano, J Rockstroh, G Dore, M Puoti, E Tedaldi, B Clotet, B Kupfer, JD Lundgren, MB Klein for the INSIGHT SMART Study Group.
    Poster 337 KB
  2. Antiretroviral Therapy (ART) Reinitiation and Hepatitis B Virus (HBV) Rebound among HIV – HBV Coinfected Patients following ART interruption in the SMART Study. V. Soriano. Poster
  3. Does Treatment Interruption within the SMART trial lead to changes in hepatitis C virus load in HIV-/HCV-coinfected patients? J Rockstroh. Poster
  4. Does Activation of Inflammatory and Coagulation Pathways Independently Predict the Development of Opportunistic Disease in Patients with HIV Infection? A Rodger. Poster

XVII International AIDS Conference, Mexico City, August 2008

Oral presentations

  1. Use of nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. JD Lundgren and the SMART/INSIGHT and D:A:D Study Groups.
    Slides 127 KB

15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008

Oral Presentations

  1. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. L and the SMART study group
    Abstract No. 139
  2. Re-initiation of antiretroviral therapy (ART) in the CD4-guided ART interruption group in the SMART study lowers risk of opportunistic disease or death. W El-Sadr and the SMART study group
    Abstract No. 36

4th IAS Conference on HIV Pathogenisis, Treatment and Prevention, Sydney, July 2007

Oral Presentations

  1. Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic therapy arm of the SMART study. G Dore, V Soriano, J Neuhaus, L Peters, M Puoti, J Rockstroh, M Klein, E Tedaldi, A Mocroft, B Clotet, JD Lundgren; For the SMART study group and INSIGHT
  2. Opportunistic disease and mortality in patients co-infected with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) in the SMART (Strategic Management of Antiretroviral Therapy) study. E Tedaldi, M Puoti, J Neuhaus, L Peters, J Rockstroh, M Klein, G Dore, A Mocroft, V Soriano, B Clotet, JD Lundgren; For the SMART study group and INSIGHT

The XVI International AIDS Conference, Toronto, August 2006

Oral Presentation

  1. Progression of HIV-related disease or death (POD) in the randomised SMART study:why was the risk of POD greater in the CD4 guided ((re)-initiate ART at CD4<250 cells/µL) drug conservation (DC) vs the virological suppression(VS) arm? Jens D. Lundgren on behalf of the SMART study group.